成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

  2. Cell Cycle/DNA Damage Apoptosis
  3. Nucleoside Antimetabolite/Analog Apoptosis
  4. Fludarabine phosphate

Fludarabine phosphate  (Synonyms: 磷酸氟達(dá)拉濱; NSC 118218 phosphate)

目錄號: HY-B0028 純度: 99.77%
COA 產(chǎn)品使用指南

Fludarabine phosphate (NSC 118218 phosphate) 是一種腺苷和脫氧腺苷類似物，與 dATP 競爭，并入到 DNA，導(dǎo)致 DNA 合成受阻。

MCE 的所有產(chǎn)品僅用作科學(xué)研究或藥證申報(bào)，我們不為任何個(gè)人用途提供產(chǎn)品和服務(wù)

Fludarabine phosphate Chemical Structure

Fludarabine phosphate Chemical Structure

CAS No. : 75607-67-9

1.  客戶無需承擔(dān)相應(yīng)的運(yùn)輸費(fèi)用。

2.  同一機(jī)構(gòu)（單位）同一產(chǎn)品試用裝僅限申領(lǐng)一次，同一機(jī)構(gòu)（單位）一年內(nèi)

     可免費(fèi)申領(lǐng)三個(gè)不同產(chǎn)品的試用裝。

3.  試用裝只面向終端客戶。

規(guī)格 價(jià)格 是否有貨 數(shù)量
10 mM * 1 mL in DMSO ￥321
In-stock
1 mg ￥226
In-stock
5 mg ￥400
In-stock
10 mg ￥600
In-stock
25 mg ￥1234
In-stock
50 mg ￥1800
In-stock
100 mg ￥2697
In-stock
200 mg ￥4163
In-stock
500 mg 現(xiàn)貨 詢價(jià)
1 g   詢價(jià)  
5 g   詢價(jià)  

* Please select Quantity before adding items.

Customer Review

Other Forms of Fludarabine phosphate:

  • 生物活性

  • 實(shí)驗(yàn)參考方法

  • 純度 & 產(chǎn)品資料

  • 參考文獻(xiàn)

生物活性

Fludarabine (phosphate) is an analogue of adenosine and deoxyadenosine, which is able to compete with dATP for incorporation into DNA and inhibit DNA synthesis.

細(xì)胞效力
(Cellular Effect)
Cell Line Type Value Description References
HeLa IC50
2 μM
Compound: fludarabine phosphate, F-ara-AMP
Antiproliferative activity against human M-HeLa cells assessed as cell growth inhibition after 48 hrs by MTT assay
Antiproliferative activity against human M-HeLa cells assessed as cell growth inhibition after 48 hrs by MTT assay
[PMID: 25960323]
HL-60 IC50
0.09 μM
Compound: fludarabine phosphate, F-ara-AMP
Antiproliferative activity against human HL60 cells assessed as cell growth inhibition after 48 hrs by MTT assay
Antiproliferative activity against human HL60 cells assessed as cell growth inhibition after 48 hrs by MTT assay
[PMID: 25960323]
K562 IC50
0.4 μM
Compound: fludarabine phosphate, F-ara-AMP
Antiproliferative activity against human K562 cells assessed as cell growth inhibition after 48 hrs by MTT assay
Antiproliferative activity against human K562 cells assessed as cell growth inhibition after 48 hrs by MTT assay
[PMID: 25960323]
KG-1 IC50
0.15 μM
Compound: fludarabine phosphate, F-ara-AMP
Antiproliferative activity against human KG1 cells assessed as cell growth inhibition after 48 hrs by MTT assay
Antiproliferative activity against human KG1 cells assessed as cell growth inhibition after 48 hrs by MTT assay
[PMID: 25960323]
MCF7 IC50
0.13 μM
Compound: fludarabine phosphate, F-ara-AMP
Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition after 48 hrs by MTT assay
Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition after 48 hrs by MTT assay
[PMID: 25960323]
MOLT-3 IC50
0.95 μM
Compound: fludarabine phosphate, F-ara-AMP
Antiproliferative activity against human MOLT3 cells assessed as cell growth inhibition after 48 hrs by MTT assay
Antiproliferative activity against human MOLT3 cells assessed as cell growth inhibition after 48 hrs by MTT assay
[PMID: 25960323]
Raji IC50
0.4 μM
Compound: fludarabine phosphate, F-ara-AMP
Antiproliferative activity against human Raji cells assessed as cell growth inhibition after 48 hrs by MTT assay
Antiproliferative activity against human Raji cells assessed as cell growth inhibition after 48 hrs by MTT assay
[PMID: 25960323]
Skut1B IC50
6 μM
Compound: fludarabine phosphate, F-ara-AMP
Antiproliferative activity against human SK-UT-1B cells assessed as cell growth inhibition after 48 hrs by MTT assay
Antiproliferative activity against human SK-UT-1B cells assessed as cell growth inhibition after 48 hrs by MTT assay
[PMID: 25960323]
ZR-75-1 IC50
0.6 μM
Compound: fludarabine phosphate, F-ara-AMP
Antiproliferative activity against human ZR-75-1 cells assessed as cell growth inhibition after 48 hrs by MTT assay
Antiproliferative activity against human ZR-75-1 cells assessed as cell growth inhibition after 48 hrs by MTT assay
[PMID: 25960323]
體外研究
(In Vitro)

Fludarabine phosphate significantly reduces the cell viability in a dose-dependent manner. Fludarabine phosphate exhibits no effect in all tested concentrations when combined with either PBS or control vector, ACE-GFP. Fludarabine phosphate causes a significant decrease in cell viability for 24 h after exposure to ACE-PNP when compared to PBS and ACE-GFP at concentrations of 2.5, 5 and 10 μg/mL[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.
體內(nèi)研究
(In Vivo)

F-araAMP (100 mg/kg given 15 times, 167 mg/kg given 9 times, or 250 mg/kg given 3 times, i.p.) leads to complete regressions of all tumors and cures of all mice. Parental D54 tumors (i.e. without E. coli PNP) are not sensitive to treatment with F-araAMP. Intratumoral injection of Ad/PNP followed by IT F-araAMP can elicit a substantial regressive effect on otherwise refractory solid tumors in a fashion substantially superior to viral PNP transduction followed by systemic prodrug administration[1]. The comparison of ACE-GFP/fludarabine phosphate with ACE-GFP/PBS demonstrats that fludarabine phosphate alone has no growth inhibitory activity on KU-19-19 tumors[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial
分子量

365.21

Formula

C10H13FN5O7P
CAS 號
性狀

固體

顏色

White to off-white

中文名稱

磷酸氟達(dá)拉濱；2-氟阿糖腺苷酸；氟達(dá)拉賓堿；氟達(dá)那苷
運(yùn)輸條件

Room temperature in continental US; may vary elsewhere.
儲存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
溶解性數(shù)據(jù)
細(xì)胞實(shí)驗(yàn)： 

DMSO 中的溶解度 : ≥ 100 mg/mL (273.82 mM; 吸濕的 DMSO 對產(chǎn)品的溶解度有顯著影響，請使用新開封的 DMSO)

H2O 中的溶解度 : 5 mg/mL (13.69 mM; 超聲助溶)

* "≥" means soluble, but saturation unknown.

配制儲備液
濃度 溶劑體積 質(zhì)量 1 mg 5 mg 10 mg
1 mM 2.7382 mL 13.6908 mL 27.3815 mL
5 mM 0.5476 mL 2.7382 mL 5.4763 mL
查看完整儲備液配制表

* 請根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲備液；一旦配成溶液，請分裝保存，避免反復(fù)凍融造成的產(chǎn)品失效。
儲備液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C儲存時(shí)，請?jiān)?個(gè)月內(nèi)使用，-20°C儲存時(shí)，請?jiān)?個(gè)月內(nèi)使用。

* 備注：如您選擇水作為儲備液，請稀釋至工作液后，再用 0.22 μm 的濾膜過濾除菌后使用。

  • 摩爾計(jì)算器

  • 稀釋計(jì)算器

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

質(zhì)量
=
濃度
×
體積
×
分子量 *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

濃度 (start)

C1

×
體積 (start)

V1

=
濃度 (final)

C2

×
體積 (final)

V2

動(dòng)物實(shí)驗(yàn)：

請根據(jù)您的 實(shí)驗(yàn)動(dòng)物和給藥方式 選擇適當(dāng)?shù)娜芙夥桨浮?

以下溶解方案都請先按照 In Vitro 方式配制澄清的儲備液，再依次添加助溶劑：
——為保證實(shí)驗(yàn)結(jié)果的可靠性，澄清的儲備液可以根據(jù)儲存條件，適當(dāng)保存；體內(nèi)實(shí)驗(yàn)的工作液，建議您現(xiàn)用現(xiàn)配，當(dāng)天使用；
以下溶劑前顯示的百分比是指該溶劑在您配制終溶液中的體積占比；如在配制過程中出現(xiàn)沉淀、析出現(xiàn)象，可以通過加熱和/或超聲的方式助溶

  • 方案 一

    請依序添加每種溶劑： phosphate buffer Saline

    Solubility: 20 mg/mL (54.76 mM); 澄清溶液; 超聲助溶

  • 方案 二

    請依序添加每種溶劑： 10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 2.5 mg/mL (6.85 mM); 澄清溶液

    此方案可獲得 ≥ 2.5 mg/mL（飽和度未知）的澄清溶液。

    以 1 mL 工作液為例，取 100 μL 25.0 mg/mL 的澄清 DMSO 儲備液加到 400 μL PEG300 中，混合均勻；再向上述體系中加入 50 μL Tween-80，混合均勻；然后再繼續(xù)加入 450 μL 生理鹽水 定容至 1 mL。

    生理鹽水的配制：將 0.9 g 氯化鈉，溶解于 ddH?O 并定容至 100 mL，可以得到澄清透明的生理鹽水溶液。

以下溶解方案，請直接配制工作液。建議現(xiàn)用現(xiàn)配，在短期內(nèi)盡快用完。 以下溶劑前顯示的百分比是指該溶劑在您配制終溶液中的體積占比； 如在配制過程中出現(xiàn)沉淀、析出現(xiàn)象，可以通過加熱和/或超聲的方式助溶。

  • 方案 一

    請依序添加每種溶劑： PBS

    Solubility: 18.33 mg/mL (50.19 mM); 澄清溶液; 超聲助溶

動(dòng)物溶解方案計(jì)算器
請輸入動(dòng)物實(shí)驗(yàn)的基本信息：

給藥劑量

mg/kg

動(dòng)物的平均體重

g

每只動(dòng)物的給藥體積

μL

動(dòng)物數(shù)量

只
由于實(shí)驗(yàn)過程有損耗，建議您多配一只動(dòng)物的量
請輸入您的動(dòng)物體內(nèi)配方組成：
%
DMSO +
% 
+
%
Tween-80 +
%
Saline
如果您的動(dòng)物是免疫缺陷鼠或者體弱鼠，建議 DMSO 中的在最后工作液體系中的占比盡量不超過 2%。
方案所需 助溶劑 包括：DMSO， ，均可在 MCE 網(wǎng)站選購。 ，Tween 80，均可在 MCE 網(wǎng)站選購。
計(jì)算結(jié)果
工作液所需濃度 : mg/mL
儲備液配制方法 : mg 藥物溶于 μL  DMSO（母液濃度為 mg/mL）。
您所需的儲備液濃度超過該產(chǎn)品的實(shí)測溶解度，以下方案僅供參考，如有需要，請與 MCE 中國技術(shù)支持聯(lián)系。
動(dòng)物實(shí)驗(yàn)體內(nèi)工作液的配制方法 : 取 μL DMSO 儲備液，加入 μL 。 μL ，混合均勻至澄清，再加 μL Tween 80，混合均勻至澄清，再加 μL 生理鹽水。
連續(xù)給藥周期超過半月以上，請謹(jǐn)慎選擇該方案。
請確保第一步儲備液溶解至澄清狀態(tài)，從左到右依次添加助溶劑。您可采用超聲加熱 （超聲清洗儀，建議頻次 20-40 kHz），渦旋吹打等方式輔助溶解。
純度 & 產(chǎn)品資料

純度: 99.77%

參考文獻(xiàn)
Cell Assay
[2]

Briefly, 2×103?KU-19-19 cells are seeded in each well of 96-well plates and allowed to grow overnight. Cells are then exposed to PBS, ACE-GFP or ACE-PNP for 3?h. Twenty-four hours post-infection, the cells are treated with various concentrations of fludarabine phosphate. After the 24-h incubation, cytotoxicity is determined by using WST-1; 4-[3-(4-iodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-1,3-benzene disulfonate. The absorbance value is determined at 450?nm by a microplate reader.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Administration
[1]

Mice: Parental and?E. coli?PNP expressing D54MG (human glioma) tumor cells (2×107?cells) are injected subcutaneously into the flanks of nude mice (nu/nu). D54 tumor cells stably transduced with?E. coli?PNP are prepared as described previously. Tumors are measured with calipers and an estimate of the weight calculated using the equation, (length × width2)/2=mm3, and converted to mg assuming unit density. Unless stated otherwise, therapeutic drugs and the adenoviral vector expressing?E. coli?PNP (Ad/PNP), or vehicle controls are injected into D54 tumors in 150 μL volumes by 8 separate injections of approximately 20 μL each in an effort to evenly distribute the administered agent. At least 6 mice are studied in each treatment group. Mice are monitored daily and body weights and tumor dimensions collected twice weekly. T-C (tumor growth delay) is determined as the difference in median days to 2 doublings (median days to 600 mg for the D54 and DU145 (human prostate cancer) analysis) between drug-treated and vehicle-treated groups. For the NIH-H322M (human non-small cell lung cancer) study, because of tumor proliferation characteristics, total growth inhibition (TGI) is used as the evaluation point. TGI is equal to the control group mean delta minus the treated group mean delta divided by the control group mean delta, where delta is the change in tumor weight for each animal between day 36 and day 59. The time to the evaluation point for each animal is used as the end point for the student's t-test, Mann-Whitney rank sum test, or a life table analysis in order to statistically compare growth data between treatment groups. All key results are repeated under similar conditions and findings confirmed. Treatments are initiated when tumors are 250 to 300 mg (appr 1-1.5% of total animal weight).

MCE has not independently confirmed the accuracy of these methods. They are for reference only.
參考文獻(xiàn)

完整儲備液配制表

* 請根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲備液；一旦配成溶液，請分裝保存，避免反復(fù)凍融造成的產(chǎn)品失效。
儲備液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C儲存時(shí)，請?jiān)?個(gè)月內(nèi)使用，-20°C儲存時(shí)，請?jiān)?個(gè)月內(nèi)使用。

可選溶劑 濃度 溶劑體積 質(zhì)量 1 mg 5 mg 10 mg 25 mg
H2O / DMSO 1 mM 2.7382 mL 13.6908 mL 27.3815 mL 68.4538 mL
5 mM 0.5476 mL 2.7382 mL 5.4763 mL 13.6908 mL
10 mM 0.2738 mL 1.3691 mL 2.7382 mL 6.8454 mL
DMSO 15 mM 0.1825 mL 0.9127 mL 1.8254 mL 4.5636 mL
20 mM 0.1369 mL 0.6845 mL 1.3691 mL 3.4227 mL
25 mM 0.1095 mL 0.5476 mL 1.0953 mL 2.7382 mL
30 mM 0.0913 mL 0.4564 mL 0.9127 mL 2.2818 mL
40 mM 0.0685 mL 0.3423 mL 0.6845 mL 1.7113 mL
50 mM 0.0548 mL 0.2738 mL 0.5476 mL 1.3691 mL
60 mM 0.0456 mL 0.2282 mL 0.4564 mL 1.1409 mL
80 mM 0.0342 mL 0.1711 mL 0.3423 mL 0.8557 mL
100 mM 0.0274 mL 0.1369 mL 0.2738 mL 0.6845 mL

* 備注：如您選擇水作為儲備液，請稀釋至工作液后，再用 0.22 μm 的濾膜過濾除菌后使用。

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

您最近查看的產(chǎn)品:

Your information is safe with us. * Required Fields.

   產(chǎn)品名稱：

  

* 需求量：

* 客戶姓名：

 

* Email：

* 電話：

 

* 公司或機(jī)構(gòu)名稱：

   留言給我們：

Bulk Inquiry

Inquiry Information

產(chǎn)品名稱：
Fludarabine phosphate
目錄號：
HY-B0028
需求量：